Prediction of response and survival after standardized treatment with 7400 MBq (177)Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

BACKGROUND AND AIMS: [(177)Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). However, identification of reliable prognostic factors is hampered by heterogeneous treatment regimens applied in previous studies. Hen...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasul, Sazan, Hartenbach, Markus, Wollenweber, Tim, Kretschmer-Chott, Elisabeth, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh, Wadsak, Wolfgang, Mitterhauser, Markus, Pichler, Verena, Vraka, Chrysoula, Hacker, Marcus, Haug, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113146/
https://www.ncbi.nlm.nih.gov/pubmed/33128131
http://dx.doi.org/10.1007/s00259-020-05082-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113146/
https://www.ncbi.nlm.nih.gov/pubmed/33128131
http://dx.doi.org/10.1007/s00259-020-05082-5

Ejemplares similares